Skip to main content

Advertisement

SpringerLink
Log in

Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature

  • Review/Case Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy, however, the adverse effects of these agents are not yet fully understood. It is generally accepted that tamoxifen, but not the aromatase inhibitors, is associated with an increased risk of thrombosis in women with breast cancer. Studies comparing aromatase inhibitors to tamoxifen in the adjuvant setting have reported a lower rate of venous thromboembolism with the aromatase inhibitors, yet the incidence of venous thromboembolism with these new agents is higher than that expected in the general population. Here we report a case of acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole, and review the literature on the incidence of venous thromboembolism during the use of aromatase inhibitors in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Heit JA (2005) Cancer and venous thromboembolism: scope of the problem. Cancer Control 12(Suppl 1):5–10

    PubMed  Google Scholar 

  2. White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93(2):298–305

    PubMed  CAS  Google Scholar 

  3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158(6):585–593

    Article  PubMed  CAS  Google Scholar 

  4. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662

    PubMed  CAS  Google Scholar 

  5. Gomes MP, Deitcher SR (2004) Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164(18):1965–1976

    Article  PubMed  CAS  Google Scholar 

  6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815

    Article  PubMed  CAS  Google Scholar 

  7. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78(5):285–291

    CAS  Google Scholar 

  8. Chew HK, Wun T, Harvey D, Zhou H, White RH (2005) The incidence of venous thromboembolism in breast cancer patients. In: Breast Cancer Res Treat, 94(Suppl 1), 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, Dec 8–11, 2005, p S13

  9. Rickles FR, Levine MN (1998) Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 28(Suppl 3):43–49

    Article  CAS  PubMed  Google Scholar 

  10. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14(10):2731–2737

    PubMed  CAS  Google Scholar 

  11. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY (1994) Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 12(6):1266–1271

    PubMed  CAS  Google Scholar 

  12. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542

    Article  PubMed  CAS  Google Scholar 

  13. Deitcher SR, Gomes MP (2004) The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101(3):439–449

    Article  PubMed  Google Scholar 

  14. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9):1802–1810

    Article  PubMed  CAS  Google Scholar 

  15. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131–2139

    Article  PubMed  CAS  Google Scholar 

  16. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60–62

    Article  PubMed  CAS  Google Scholar 

  17. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757

    Article  PubMed  Google Scholar 

  18. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092

    Article  PubMed  CAS  Google Scholar 

  19. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462

    Article  PubMed  CAS  Google Scholar 

  20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802

    Article  PubMed  CAS  Google Scholar 

  21. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271

    Article  PubMed  CAS  Google Scholar 

  22. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23(22):5138–5147

    Article  PubMed  CAS  Google Scholar 

  23. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, Bertolini S, Rosso R (1988) Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12(3):307–310

    Article  PubMed  CAS  Google Scholar 

  24. Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V et al (1992) Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer 29A(1):15–21

    PubMed  CAS  Google Scholar 

  25. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, Singh R (1996) The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7(7):671–675

    PubMed  CAS  Google Scholar 

  26. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U (1996) Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 156(16):1806–1810

    Article  PubMed  CAS  Google Scholar 

  27. Jones AL, Powles TJ, Treleaven JG, Burman JF, Nicolson MC, Chung HI, Ashley SE (1992) Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 66(4):744–747

    PubMed  CAS  Google Scholar 

  28. Love RR, Surawicz TS, Williams EC (1992) Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 152(2):317–320

    Article  PubMed  CAS  Google Scholar 

  29. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN (2003) Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 120(1):109–116

    Article  PubMed  CAS  Google Scholar 

  30. Pemberton KD, Melissari E, Kakkar VV (1993) The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 4(6):935–942

    Article  PubMed  CAS  Google Scholar 

  31. Oberhoff C, Szymeczek J, Hoffmann O, Winkler UH, Kaiser S, Schindler AE (1998) Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat 50(1):73–81

    Article  PubMed  CAS  Google Scholar 

  32. Miller J, Chan BK, Nelson HD (2002) Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 136(9):680–690

    PubMed  CAS  Google Scholar 

  33. Kujovich JL (2004) Hormones and pregnancy: thromboembolic risks for women. Br J Haematol 126(4):443–454

    Article  PubMed  Google Scholar 

  34. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN (2001) Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 21(2):255–261

    PubMed  CAS  Google Scholar 

  35. Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A, Salter J et al (2002) Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20(4):1026–1035

    Article  PubMed  CAS  Google Scholar 

  36. Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J (1995) Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1(3):287–294

    PubMed  CAS  Google Scholar 

  37. Brodie A, Lu Q, Long B (1999) Aromatase and its inhibitors. J␣Steroid Biochem Mol Biol 69(1–6):205–210

    Article  PubMed  CAS  Google Scholar 

  38. Bajetta E, Zilembo N, Dowsett M, Guillevin L, Di Leo A, Celio L, Martinetti A, Marchiano A, Pozzi P, Stani S et al (1999) Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 35(2):208–213

    Article  PubMed  CAS  Google Scholar 

  39. Costa LA, Kopreski MS, Demers LM, Chinchilli VM, Santen RJ, Harvey HA, Lipton A (1999) Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Cancer 85(1):100–103

    Article  PubMed  CAS  Google Scholar 

  40. Oyan B, Altundag K, Ozisik Y (2004) Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability? Am J Clin Oncol 27(2):210–211

    Article  PubMed  Google Scholar 

  41. Diab SG, Elledge RM, Clark GM (2000) Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92(7):550–556

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Mailcode L586, Portland, OR, 97239, USA

    Jennifer L. Lycette, Tomasz M. Beer & Thomas G. Deloughery

  2. Division of Hematology and Medical Oncology, Oregon Health & Science University and Portland VA Medical Center, Portland, OR, USA

    Jennifer L. Lycette & Shiuh-Wen Luoh

Authors
  1. Jennifer L. Lycette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiuh-Wen Luoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomasz M. Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas G. Deloughery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer L. Lycette.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lycette, J.L., Luoh, SW., Beer, T.M. et al. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature. Breast Cancer Res Treat 99, 249–255 (2006). https://doi.org/10.1007/s10549-006-9212-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9212-1

Keywords

Search

Navigation